← Back to headlines
Gilead Sciences Acquires Ouro Medicines for $2.2 Billion to Boost T-Cell Therapy
Gilead Sciences is set to acquire biotech firm Ouro Medicines in a deal valued at $2.2 billion, marking its first TCE asset acquisition and aiming to boost its T cell therapy capabilities for autoimmune diseases.
23 Mar, 22:28 — 24 Mar, 17:32
The Story
Analyzing sources…
Source Diversity
Source Diversity
High (51/100)3 sources25/33
Spectrum spread— 3/5 buckets covered17/33
Far L
Left1
Left (1)
Yahoo
Center1
Center (1)
Reuters
Right1
Right (1)
seeking-alpha
Far R
Geographic diversity— 2 regions9/34
US2Intl1
Sources
Showing 3 of 3 sources
ReutersVery High138d ago
Gilead to buy biotech firm Ouro Medicines in over $2 billion deal - Reuters
Gilead to buy biotech firm Ouro Medicines in over $2 billion deal Reuters
Read full article →YahooMostly Factual138d ago
Gilead acquires first TCE asset with $2.2bn Ouro Medicines buyout
Read full article →seeking-alphaMixed138d ago
Gilead Sciences to buy Ouro Medicines to boost T cell therapy for autoimmune diseases
Read full article →Coverage Timeline
First report: Reuters · 23 Mar, 22:28|Full coverage: 3 · 19h|Window: 19h
Left-leaningCenterRight-leaning
